Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

18 results about "Insulin receptor" patented technology

The insulin receptor (IR) is a transmembrane receptor that is activated by insulin, IGF-I, IGF-II and belongs to the large class of tyrosine kinase receptors. Metabolically, the insulin receptor plays a key role in the regulation of glucose homeostasis, a functional process that under degenerate conditions may result in a range of clinical manifestations including diabetes and cancer. Insulin signalling controls access to blood glucose in body cells. When insulin falls, especially in those with high insulin sensitivity, body cells begin only to have access to lipids that do not require transport across the membrane. So, in this way, insulin is the key regulator of fat metabolism as well. Biochemically, the insulin receptor is encoded by a single gene INSR, from which alternate splicing during transcription results in either IR-A or IR-B isoforms. Downstream post-translational events of either isoform result in the formation of a proteolytically cleaved α and β subunit, which upon combination are ultimately capable of homo or hetero-dimerisation to produce the ≈320 kDa disulfide-linked transmembrane insulin receptor.

Application of PBX1 in preparation of medicine or medical apparatus for treating type 2 diabetes mellitus

The invention relates to an application of PBX1 as an active component in preparation of type 2 diabetes mellitus drugs or medical instruments, so as to relieve symptoms of diabetes mellitus, promote repair and regeneration of damaged pancreas islets and improve functions of insulin. The symptoms comprise water intake, food intake and fasting blood glucose; the method for promoting the repair and regeneration of the damaged pancreas islet comprises the steps of inhibiting the apoptosis of pancreas islet beta cells of diabetic mice, promoting the proliferation of the beta cells and recovering the tissue structure of the damaged pancreas islet; the function of improving the pancreas islet comprises the steps of stimulating secretion of insulin, improving the level of an insulin receptor, promoting absorption of an organism to glucose and reducing serum hyperglycemia and HbA1c concentration of diabetic mice, so that the effect of treating both symptoms and root causes of diabetes is achieved.
Owner:JILIN UNIVERSITY

Group of GLP-1R transmembrane domain mimic peptides and application thereof

The invention discloses a group of GLP-1R transmembrane domain mimic peptides and application thereof, and belongs to the technical field of polypeptides. The invention aims to solve the technical problem of how to interfere formation of GLP-1R and IR heteropolymers and further realize targeted prevention or / and treatment of metabolic diseases such as type 2 diabetes mellitus, obesity, insulin resistance, fatty liver and the like. In order to solve the technical problem, the invention provides a polypeptide composition or polypeptide for interfering formation of GLP-1R and IR heteropolymers. The invention develops a transmembrane domain heterodimer regulation direction aiming at a brand new action interface of the heterodimer of a glucagon-like peptide-1 receptor (GLP-1R) and an insulin receptor (IR) for the first time. Meanwhile, the polypeptide provided by the invention can also influence the interaction between the GLP-1R and the polymer.
Owner:OPEN UNIVERSITY OF CHINA

Preparation method of radix ophiopogonis oligosaccharide

PendingCN121108375AOrganic active ingredientsSugar derivativesMedicinal herbsMetformin Hydrochloride
The invention discloses a preparation method of radix ophiopogonis oligosaccharide, which comprises the following steps: taking a proper amount of radix ophiopogonis medicinal material, adding water to extract twice at the material-liquid ratio of 1: (6-10) and the extraction temperature of 90-100 DEG C for 1-2 hours each time, and concentrating the filtrate to prepare extract; adding 40% ethanol for alcohol precipitation, and concentrating filtrate to prepare extract; and adding 80% ethanol for alcohol precipitation, washing the precipitate with 95% ethanol, and drying the precipitate to obtain the product. According to the method, the molecular weight can be controlled to be 1000 or below, and the activity and safety of resisting type 2 diabetes mellitus are higher. According to the present invention, the expression of the insulin receptor and the substrate thereof can be improved, the sensitization effect on the insulin is significantly better than the metformin hydrochloride and the pyrrolitazone hydrochloride, and the blank of the diabetes caused by the insulin receptor and the substrate defect in the treatment drug can be filled. The preparation process is stable and controllable, the product yield is high, and good conditions are provided for quality control and industrial application of the radix ophiopogonis oligosaccharide.
Owner:CHINESE MEDICINE GUANGDONG LABORATORY +1

Method for lowering blood glucose level

A method for lowering blood glucose level includes administering to a subject in need thereof a composition containing a Momordica charantia—derived exosome and a Momordica charantia insulin receptor-binding protein. A weight ratio of the Momordica charantia—derived exosome to the Momordica charantia insulin receptor-binding protein ranges from 2:1 to 5:1. The composition is a food product or a pharmaceutical composition.
Owner:BAOSHENG BIOMEDICAL RESEARCH CO LTD +1

Combination therapy for diseases or disorders associated with PI3k

To provide a method for treating diseases or disorders associated with PI3K signaling.SOLUTION: A method for inhibiting cell proliferation includes the steps of: bringing a cell in contact with an effective dose of a regulating substance of glucose metabolism; and bringing the cell in contact with an effective dose of at least one inhibitory substance of at least one kinase in an insulin receptor / PI3K / AKT / mTOR pathway, by which cell proliferation is inhibited.SELECTED DRAWING: Figure 10A
Owner:CORNELL UNIVERSITY +1

De novo designed protein binders and modulators of the insulin receptor

PCT designated stageWO2026075904A1Antibody mimetics/scaffoldsMetabolism disorderPancreatic hormoneInsulin receptor
Polypeptides are disclosed having an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from SEQ ID NO: 1-28, not including any amino acid insertions at identified insertion sites, wherein the polypeptide binds to the F 1 domain of insulin receptor; or SEQ ID NO: 29-31, wherein the polypeptide binds to the LI domain of insulin receptor; fusion proteins thereof, and. methods for their use.
Owner:UNIV OF WASHINGTON +2

Insulin derivatives

Novel derivatives of human insulin are described that have binding affinities for the IGF-1 receptor surprisingly comparable to human IGF-1, while having higher affinities for both isoforms of the insulin receptor than human insulin. The novel insulin derivatives have D-histidine or glycine at position B24, the B chain has glycine at the C-terminus at position B31 and tyrosine at position B32, and glutamic or aspartic acid at position B10. The derivatives of the invention can be used particularly for growth and proliferation stimulation in cell cultures or for treatment of neurological disorders as of Alzheimer's disease, Huntington's and Parkinson's diseases, a cognitive loss or symptoms of syndromic autism, since one derivative could mediate both insulin and IGF-1 function.
Owner:USTAV ORGANICKE CHEM A BIOCHEM AKADE VED CR V V I

Glucose-responsive insulin analogs and methods of use thereof

The subject matter of this invention is directed towards insulin analogs that are stable and glucose-responsive. An insulin analog can be a single chain insulin (SCI). The binding affinity of insulin to the insulin receptor can be controlled by the glucose-bound conformation of insulin. The invention further discloses methods for the recombinant expression, purification, and refolding of an insulin analog.
Owner:AMIDEBIO LLC

Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant fc fusion proteins

ActiveUS12714739B2DyslipidemiaCritically ill
The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and / or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.
Owner:NOVARTIS AG

A uorf element for regulating expression of chicken insulin receptor and application thereof

ActiveCN120796258BEucaryotic cellLow insulin
The application discloses a uORF element for regulating chicken insulin receptor expression and application thereof, belongs to the field of molecular biology and genetic engineering, and the nucleotide sequence of the uORF element is shown in any one of SEQ ID NO. 1-2; the application comprises any one of the following: (1) regulating the expression of firefly luciferase in eukaryotic cells; the eukaryotic cells are chicken embryo fibroblasts and chicken preadipocytes; (2) being applied to genetic breeding of chickens, and the genetic breeding is breeding of meat chickens with reduced insulin resistance; (3) application in preparation of a reagent for regulating the expression of chicken insulin receptors. The application can regulate the expression level of INSR, improve insulin sensitivity, and provide material support for research on the mechanism of insulin in regulating blood glucose.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Novel insulin receptor (INSR) small molecule agonists as antidiabetic agents

Provided herein are insulin receptor (INSRF) agonist compounds of Formula I-IV or compositions containing the same, the use of these compounds or compositions in the treatment of diabetes. These compounds and compositions can bind to allosteric sites on INSR and cooperate with insulin to activate INSR and downstream signaling pathways by phosphorylating the INSR protein.
Owner:THE UNIVERSITY OF HONG KONG +1

Anti-inflammatory hypoglycemic food based on potato peptide and preparation method of anti-inflammatory hypoglycemic food

InactiveCN121176637AConfectionerySweetmeatsIslet cellsNojirimycin
The invention belongs to the technical field of functional foods, and particularly relates to an anti-inflammatory hypoglycemic food based on potato peptide and a preparation method thereof, and the preparation method comprises the following steps: S1, preparing potato peptide by taking potato protein as a raw material, and performing pretreatment, composite enzymolysis, centrifugal separation, ultrafiltration purification and spray drying to obtain small molecular potato peptide; s2, pretreatment of auxiliary materials: the prebiotics, the deoxynojirimycin, the functional sweetening agent, the dietary fibers, the compound vitamins and the compound minerals are crushed, screened or dissolved respectively, and the potato peptide is used as a core raw material, so that pancreatic beta cell proliferation can be promoted, insulin receptor sensitivity can be improved, the potato peptide directly acts on blood sugar regulation, and the effect of improving the insulin receptor sensitivity is achieved; the problem that an existing blood sugar reducing food only controls sugar and cannot intervene in the pain point of inflammation is solved, vicious circle of inflammation and hyperglycemia is avoided so as to meet the pathological requirements of diabetics, and the blood sugar reducing food is superior to traditional blood sugar reducing food depending on dietary fibers or single plant extracts.
Owner:JILIN MAOQUANSHUBAO BIOTECHNOLOGY DEVELOPMENT CO LTD

Application of glycerol monodecanoate in preparation of hypoglycemic drug or functional food

Disclosed is an application of glycerol monodecanoate (GMD) in the preparation of a hypoglycemic drug or a functional food, falling within the technical field of medicine. According to the present disclosure, the hypoglycemic and insulin resistance-improving functions of GMD are first revealed. Studies demonstrate that GMD can enhance glucagon-like peptide-1 (GLP-1) secretion, activate hepatic glycolysis and insulin receptor (INSR)-related gene expression, while inhibiting hepatic gluconeogenesis pathway-related gene expression. Notably in type 2 diabetes mellitus (T2DM), glucose-lowering efficacy of GMD is comparable to metformin, and it outperforms metformin in regulating glucose tolerance and insulin tolerance, with significant alleviation of polydipsia. Moreover, as GMD is a naturally occurring edible substance with a high safety profile, it has a good application prospect in the preparation of a drug for treating hyperglycemia and diabetes, or a functional food to assist in lowering blood glucose.
Owner:HANGZHOU KANGYUAN FOOD SCI & TECH +1

Long-acting insulin-Fc fusion protein

The present invention provides long-acting insulin-Fc fusion proteins, which have reduced insulin receptor affinity, increased growth factor receptor selectivity, and a prolonged half-life in the body, which can extend the duration of blood glucose reduction in the body, shorten the interval between insulin doses, and reduce side effects such as the risk of hypoglycemia.
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES

Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome

Novel insulin, insulin-fusion proteins and insulin homologs protein-small molecule drug conjugates, where conjugation takes place through the use of cleavable and non-cleavable linkers are disclosed. The small molecules chemically linked to the protein carrier are imported into the specific insulin-responsive target tissue or cell through receptor-mediated endocytosis and released from the carrier protein through enzymatic cleavage of the linker-drug moiety or through lysosomal degradation of the carrier protein. Free drug can then act to modify insulin receptor-triggered biochemical pathways that are altered in conditions of insulin-resistance. Drug will correct altered pathway allowing re-sensitization of receptor signaling. This will greatly aid in the resolution of pathologies either initiated at the onset of insulin resistance or exacerbated by it.
Owner:LINK THERAPEUTICS LLC

UORF element for regulating expression of chicken insulin receptor and application of uORF element

ActiveCN120796258AVectorsPeptidesEucaryotic cellLow insulin
The invention discloses a uORF element for regulating and controlling expression of a chicken insulin receptor and application of the uORF element, and belongs to the field of molecular biology and genetic engineering, and the nucleotide sequence of the uORF element is shown as any one of SEQ ID NO.1-2; the application comprises any one of the following applications: (1) regulating and controlling expression of firefly luciferase in eukaryotic cells; the eukaryotic cells are chicken embryo fibroblasts and chicken preadipocytes; (2) the method is applied to genetic breeding of chickens, and the genetic breeding refers to breeding of broiler chickens capable of reducing insulin resistance; and (3) application in preparation of a reagent for regulating expression of the chicken insulin receptor. The expression level of INSR can be regulated and controlled, insulin sensitivity is improved, and material support is provided for research on analysis of a mechanism for regulating and controlling blood sugar by insulin.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Composition for use in lowering blood glucose level

A composition containing a Momordica charantia-derived exosome and a Momordica charantia insulin receptor-binding protein for use in lowering blood glucose level in a subject in need thereof. A weight ratio of the Momordica charantia-derived exosome to the Momordica charantia insulin receptor-binding protein ranges from 2:1 to 5:1. The composition is a food product or a pharmaceutical composition.
Owner:BAOSHENG BIOMEDICAL RESEARCH CO LTD +2